Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 7, 2011

View Archived Issues

BD Diagnostics files for FDA clearance for fully automated molecular assays for herpes

New antagonists of melanin-concentrating hormone MCH1 receptor claimed

New inhibitors of FADK 1, JAK2 and JAK3 described

X-ray crystallography provides insight into formation of complement convertase

Triheptanoin has anticonvulsant effects in models of epilepsy

PanOptica raises funds to develop topical treatment for AMD

Insulin PharmFilm is tested in primates

Mercator Therapeutics and Pepscan Therapeutics join to optimize anticancer homing peptides

Almirall and Forest Labs report on aclidinium bromide trials

AnaptysBio triggers milestone payment from Merck & Co.

Bioniche Life Sciences raises funds to support several programs

Anadys begins phase IIb study of ANA-598 in hepatitis C

FDA lifts clinical hold on phase II Alferon LDO trial in influenza

Cellzome researchers describe novel ZAP-70 inhibitors

Invega approved in E.U. for schizoaffective disorder

Novel B-raf inhibitors discovered at Nerviano Medical Sciences

New ligands of transient receptor potential TRPM8 channel patented

Santarus and Depomed resume Glumetza distribution in U.S.

SuperGen enrolls first patient in phase I SGI-110 trial in MDS and AML

Omeros licenses new antifibrinolytic agents from University of California

Algeta completes enrollment into phase III Alpharadin trial

Avila Therapeutics designs irreversible and selective HCV protease inhibitors

Enrollment complete in EXPAND trial of Erbitux in gastric cancer

Cynapsus and IntelGenx sign definitive license agreement for INT-0010

Gold-bound TNF-alpha formulation CYT-6091 enters clinic

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Latus Bio series A financing supports early-stage programs
BioWorld Science
Latus Bio Inc. has closed a $97 million series A financing to support its broad therapeutics pipeline based on novel AAV capsid variants. Proceeds from the...